✦ LIBER ✦

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

✍ Scribed by Larson, R A; Hochhaus, A; Hughes, T P; Clark, R E; Etienne, G; Kim, D-W; Flinn, I W; Kurokawa, M; Moiraghi, B; Yu, R; Blakesley, R E; Gallagher, N J; Saglio, G; Kantarjian, H M

Book ID: 111898859
Publisher: Nature Publishing Group
Year: 2012
Tongue: English
Weight: 351 KB
Volume: 26
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2012.134

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Nilotinib as frontline therapy for patie

Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd

✍ Hirohisa Nakamae; Hirohiko Shibayama; Mineo Kurokawa; Tetsuya Fukuda; Chiaki Nak 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 289 KB

Imatinib mesylate therapy improves survi

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase : Comparison with historic data

✍ Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Francis J. Giles; Mary Beth Ri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

## Abstract ## BACKGROUND The International Randomized study of Interferon‐alpha plus cytarabine (IFN‐α plus ara‐C) versus STI571 (imatinib mesylate) [IRIS trial] in patients with newly diagnosed Philadelphia chromosome (Ph)‐positive, chronic‐phase chronic myelogenous leukemia (CML) has not shown

P107 Chromosomal abnormalities in Philad

P107 Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase

✍ S. Jootar 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 51 KB

6/155), high white cell number (13/155) (red cell unit) or low thrombocyte number (14/125) (thrombocyte unit). Summary: Donors with low hemoglobin levels have to be excluded from the blood donation service for 3 months. So, in theory haemoglobin concentration of all total blood units is suitable for

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH